Sanofi completes acquisition of Inhibrx, Inc. to enhance rare disease pipeline
Acquiring Company
Sanofi
Acquired Company
Inhibrx
San DiegoBiotechnologyHealth CareMedicalPharmaceuticalBiotechnologyTherapeuticsBiopharmaDescription
Sanofi has successfully completed its acquisition of Inhibrx, Inc. The acquisition adds SAR447537 to Sanofi’s rare disease pipeline, aiming to provide better treatment options for AATD patients and strengthen Sanofi’s capabilities in the healthcare sector.
Quick answer
Sanofi is acquiring Inhibrx, announced May 30, 2024.
- How much did Sanofi pay for Inhibrx?
- The deal value was not disclosed.
- What does Sanofi do?
- LONDON--(BUSINESS WIRE)--Gyroscope Therapeutics Holdings plc (Gyroscope), a clinical-stage gene therapy company focused on diseases of the eye, today announced that Sanofi, a global biopharmaceutical company, has..
- Where are Sanofi and Inhibrx based?
- Inhibrx is based in San Diego, California, United States.
- Who are the decision-makers at Sanofi?
- Fundz holds 4 contacts at Sanofi. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Medical and Pharmaceutical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- AbbVie finalizes acquisition of Landos Biopharma, Inc. to advance treatment for ulcerative colitis and Crohn's disease (May 23, 2024)
- Cycle Pharmaceuticals proposes to acquire Vanda Pharmaceuticals for $8.00 per share (June 6, 2024)
- Harmony Biosciences acquires Epygenix Therapeutics, Inc. to expand rare epilepsy franchise (April 30, 2024)
- Future Pak proposes acquisition of Vanda Pharmaceuticals for $7.25 to $7.75 per share in cash (April 17, 2024)
- Lilly completes acquisition of Morphic to enhance immunology pipeline (July 8, 2024)
- Ligand Pharmaceuticals to acquire APEIRON Biologics AG to enhance royalty portfolio (July 8, 2024)
Who to call at Sanofi, and when
When Sanofi changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Sanofi raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Sanofi, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Sanofi. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Sanofi makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Inhibrx?
Inhibrx was acquired by Sanofi. The deal was reported on May 30, 2024. Sanofi is publicly traded (SNY) and operates in Biotechnology.
When did Sanofi acquire Inhibrx?
Sanofi's acquisition of Inhibrx was reported on May 30, 2024. Sanofi has successfully completed its acquisition of Inhibrx, Inc. The acquisition adds SAR447537 to Sanofi’s rare disease pipeline, aiming to provide better treatment options for AATD patients and strengthen Sanofi’s capabilities in the healthcare sector. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Inhibrx do?
Inhibrx is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. It is privately held, operating in Biotechnology, and is based in San Diego.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.